Zhang YJ, Wu SP. Therapeutic effect of Wendan Decoction combined with mosapride on gastroesophageal reflux disease after esophageal cancer surgery. World J Clin Cases 2024; 12(13): 2194-2200 [PMID: 38808341 DOI: 10.12998/wjcc.v12.i13.2194]
Corresponding Author of This Article
Yu-Jing Zhang, MM, Attending Doctor, Department of Oncology, Beijing Integrated Traditional Chinese and Western Medicine Hospital, No. 3 East Street, Yongding Road, Haidian District, Beijing 100039, China. tzvz674@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. May 6, 2024; 12(13): 2194-2200 Published online May 6, 2024. doi: 10.12998/wjcc.v12.i13.2194
Therapeutic effect of Wendan Decoction combined with mosapride on gastroesophageal reflux disease after esophageal cancer surgery
Yu-Jing Zhang, Shen-Ping Wu
Yu-Jing Zhang, Shen-Ping Wu, Department of Oncology, Beijing Integrated Traditional Chinese and Western Medicine Hospital, Beijing 100039, China
Author contributions: Zhang YJ and Wu SP proposed the concept of this study; Wu SP participated in the data collection; Zhang YJ and Wu SP wrote the initial draft; Wu SP contributed to the formal analysis; Zhang YJ conducted guiding research, methodology, and visualization of the manuscript; Both authors participated in this study, validated it, and jointly reviewed and edited the manuscript.
Institutional review board statement: This study has been reviewed and approved by the Ethics Committee of Beijing Integrated Traditional Chinese and Western Medicine Hospital
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: We declare that there is no disclosure of any conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu-Jing Zhang, MM, Attending Doctor, Department of Oncology, Beijing Integrated Traditional Chinese and Western Medicine Hospital, No. 3 East Street, Yongding Road, Haidian District, Beijing 100039, China. tzvz674@163.com
Received: January 25, 2024 Peer-review started: January 25, 2024 First decision: February 8, 2024 Revised: February 9, 2024 Accepted: March 27, 2024 Article in press: March 27, 2024 Published online: May 6, 2024 Processing time: 91 Days and 3.1 Hours
Abstract
BACKGROUND
Gastroesophageal reflux disease (GERD) is a common complication of esophageal cancer surgery that can affect quality of life and increase the risk of esophageal stricture and anastomotic leakage. Wendan Decoction (WDD) is a traditional Chinese herbal formula used to treat various gastrointestinal disorders, such as gastritis, functional dyspepsia, and irritable bowel syndrome. Mosapride, a prokinetic agent, functions as a selective 5-hydroxytryptamine 4 agonist, enhancing gastrointestinal motility.
AIM
To evaluate the therapeutic effects of WDD combined with mosapride on GERD after esophageal cancer surgery.
METHODS
Eighty patients with GERD were randomly divided into treatment (receiving WDD combined with mosapride) and control (receiving mosapride alone) groups. The treatment was conducted from January 2021 to January 2023. The primary outcome was improved GERD symptoms as measured using the reflux disease questionnaire (RDQ). The secondary outcomes were improved esophageal motility (measured using esophageal manometry), gastric emptying (measured using gastric scintigraphy), and quality of life [measured via the Short Form-36 (SF-36) Health Survey].
RESULTS
The treatment group showed a notably reduced RDQ score and improved esophageal motility parameters, such as lower esophageal sphincter pressure, peristaltic amplitude, and peristaltic velocity compared to the control group. The treatment group showed significantly higher gastric emptying rates and SF-36 scores (in both physical and mental domains) compared to the control group. No serious adverse effects were observed in either group.
CONCLUSION
WDD combined with mosapride is an effective and safe therapy for GERD after esophageal cancer surgery. It can improve GERD symptoms, esophageal motility, gastric emptying, and the quality of life of patients. Further studies with larger sample sizes and longer follow-up periods are required to confirm these findings.
Core Tip: This study suggests that combining Wendan Decoction with mosapride is an effective and safe therapy for managing gastroesophageal reflux disease (GERD) after esophageal cancer surgery. It improves GERD symptoms, esophageal motility, gastric emptying, and the quality of life of patients. Larger studies with longer follow-up periods are needed to further validate these findings.
